

Title (en)
NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS

Title (de)
NEUE 2,4-DIANILINOPYRIMIDINDERIVATE, IHRE HERSTELLUNG, IHRE VERWENDUNG ALS MEDIKAMENTE, PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND INSBESONDERE ALS IKK-INHIBITOREN

Title (fr)
NOUVEAUX DERIVES DE 2,4-DIANILINOPYRIMIDINES, LEUR PREPARATION, A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOTAMMENT COMME INHIBITEURS DE IKK

Publication
EP 1904479 A2 20080402 (FR)

Application
EP 06778795 A 20060706

Priority

- FR 2006001619 W 20060706
- FR 0507370 A 20050711
- FR 0511950 A 20051125

Abstract (en)
[origin: WO2007006926A2] The invention relates to products of formula (I) in which: R2, R3 and R4 represent one hydrogen and the others represent hydrogen, halogen, alkyl or alkoxy; R5 represents hydrogen or halogen; R1 represents hydrogen, cycloalkyl, alkyl, alkenyl or alkynyl, all of which being optionally substituted; A represents a single bond or -CH2-CO-NR6- with R6 being selected among the values of R1; the cycle containing Y (or (Y) cycle)) having 4 to 8 members with Y representing O, S, SO, SO2, N-R7 ((Y) cycle) that can contain a carbon bridge), C=O or the dioxolane therefor, CF2, CH-OR8, CH-NR8R9, and; R7 represents hydrogen, cycloalkyl, alkyl, CH2-alkenyl or CH2-alkynyl, all of which being optionally substituted; R8 represents hydrogen, alkyl, cycloalkyl or heterocycloalkyl, all of which being optionally substituted, these products existing in all isomeric forms and the salts. The invention also relates to the use of the aforementioned derivatives as medicaments, in particular, as IKK inhibitors.

IPC 8 full level
C07D 401/12 (2006.01); **A61K 31/351** (2006.01); **A61K 31/381** (2006.01); **A61K 31/506** (2006.01); **C07D 403/12** (2006.01); **C07D 405/12** (2006.01); **C07D 409/12** (2006.01)

CPC (source: EP KR US)
A61K 31/506 (2013.01 - KR); **A61P 3/10** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 401/12** (2013.01 - EP KR US); **C07D 401/14** (2013.01 - EP KR US); **C07D 403/12** (2013.01 - EP US); **C07D 405/12** (2013.01 - EP US); **C07D 409/12** (2013.01 - EP US); **C07D 413/12** (2013.01 - EP US); **C07D 413/14** (2013.01 - EP US); **C07D 417/12** (2013.01 - EP US); **C07D 417/14** (2013.01 - EP US); **C07D 471/08** (2013.01 - EP US); **C07D 471/14** (2013.01 - EP US); **C07F 9/65583** (2013.01 - EP US)

Citation (search report)
See references of WO 2007006926A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)
AL BA HR MK YU

DOCDB simple family (publication)
WO 2007006926 A2 20070118; WO 2007006926 A3 20070322; AU 2006268531 A1 20070118; BR PI0613452 A2 20110111; CA 2614597 A1 20070118; CR 9602 A 20080305; EA 200800285 A1 20080829; EC SP078064 A 20080123; EP 1904479 A2 20080402; IL 188494 A0 20080413; JP 2009501711 A 20090122; KR 20080027832 A 20080328; MA 29649 B1 20080701; MX 2008000574 A 20080314; NO 20080456 L 20080304; NZ 564872 A 20100129; TN SN07471 A1 20090317; US 2008269170 A1 20081030

DOCDB simple family (application)
FR 2006001619 W 20060706; AU 2006268531 A 20060706; BR PI0613452 A 20060706; CA 2614597 A 20060706; CR 9602 A 20071218; EA 200800285 A 20060706; EC SP078064 A 20071228; EP 06778795 A 20060706; IL 18849407 A 20071230; JP 2008520910 A 20060706; KR 20087000779 A 20080110; MA 30603 A 20080128; MX 2008000574 A 20060706; NO 20080456 A 20080124; NZ 56487206 A 20060706; TN SN07471 A 20071214; US 97138908 A 20080109